

Vertiseit - FX hurting in 2025 – Solid otherwise

Redeye retains its positive view of Vertiseit following a Q1 report where FX and a higher headcount than expected hurt margins in Q1 and 2025. However, the important FX-adjusted organic ARR growth was strong, and the outlook is promising.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vertiseit - FX hurting in 2025 - Solid otherwise